Purinergic signaling in osteoarthritis: Mechanistic insights into pathogenesis and therapeutic targeting
Open Access
- 1 September 2026
- journal article
- review article
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (5) , 102002
Abstract
Osteoarthritis (OA) is a degenerative joint disease driven by a complex interplay of inflammation, extracellular matrix degradation, subchondral bone remodeling, and chronic pain. Purinergic signaling has emerged as a key regulator of OA pathogenesis, where dysregulated extracellular nucleotide-mediated P2 receptor activation and impaired adenosine-mediated P1 receptor signaling disrupt joint homeostasis. Excessive activation of P2X and P2Y receptors amplifies inflammatory cascades, promotes chondrocyte apoptosis, enhances matrix metalloproteinase activity, and sensitizes nociceptive pathways, while reduced P1 receptor signaling, particularly via A2A and A3, compromises anti-inflammatory and chondroprotective mechanisms. Additionally, disruptions in extracellular nucleotide metabolism exacerbate disease progression by perpetuating synovial fibrosis, cartilage destruction, and persistent pain. This review provides a mechanistic overview of purinergic receptor dysregulation in OA, detailing its roles in synovial inflammation, cartilage homeostasis, subchondral bone remodeling, and pain transmission. Furthermore, this review explores emerging therapeutic strategies targeting purinergic receptors, particularly P2 receptor antagonists and P1 receptor agonists, which are being developed as selective ligands to restore joint homeostasis and attenuate disease progression. Understanding the intricate molecular crosstalk between the P2 and P1 receptor pathways will be critical for the development of precision therapies aimed at modifying OA pathophysiology and improving clinical outcomes.Keywords
Funding Information
- Sichuan Provincial Science and Technology Support Program (2022YFS0628)
- Southwest Medical University
- Chongqing Medical University
This publication has 200 references indexed in Scilit:
- Plasma Proteomic Profiles Predict Individual Future Osteoarthritis RiskArthritis & Rheumatology, 2025
- P2X4 receptor modulates gut inflammation and favours microbial homeostasis in colitisClinical and Translational Medicine, 2023
- Purinergic receptors modulators: An emerging pharmacological tool for disease managementMedicinal Research Reviews, 2022
- Sinomenine increases adenosine A2A receptor and inhibits NF-κB to inhibit arthritis in adjuvant-induced-arthritis rats and fibroblast-like synoviocytes through α7nAChRJournal of Leukocyte Biology, 2021
- Diagnosis and Treatment of Hip and Knee OsteoarthritisJAMA, 2021
- Purinergic Signaling: Impact of GPCR Structures on Rational Drug DesignChemMedChem, 2020
- Genome‐Wide Occupancy Profiling Reveals Critical Roles of FoxO1 in Regulating Extracellular Matrix and Circadian Rhythm Genes in Human ChondrocytesArthritis & Rheumatology, 2020
- Acupuncture induces adenosine in fibroblasts through energy metabolism and promotes proliferation by activating MAPK signaling pathway via adenosine3 receptorJournal of Cellular Physiology, 2019
- Methylosome protein 50 associates with the purinergic receptor P2X5 and is involved in osteoclast maturationFEBS Letters, 2019
- Expression of both P1 and P2 purine receptor genes by human articular chondrocytes and profile of ligand-mediated prostaglandin E2 releaseArthritis & Rheumatism, 1999